Table 1.
Baseline clinical and procedural characteristics of study patients
| Characteristics | Basic treatment Group (n=51) | Standard CS therapy Group (n=49) | Intensive CS therapy Group (n=50) | F/χ2 | P |
|---|---|---|---|---|---|
| Gender (Men/Women) | 27/24 | 28/21 | 26/24 | 0.723 | 0.53 |
| Age (yrs) | 64.59±5.72 | 63.95±4.27 | 65.13±6.26 | 0.685 | 0.48 |
| BMI (kg/m2) | 27.19±5.72 | 26.91±6.24 | 28.03±8.07 | 0.383 | 0.32 |
| Hemoglobin (g/L) | 129.18±10.18 | 130.18±9.76 | 132.18±11.39 | 0.463 | 0.39 |
| Hypertension (%) | 33 (64.71) | 32 (65.31) | 34 (68.00) | 0.117 | 0.18 |
| Cholesterol (mmol/L) | 4.83±1.24 | 4.76±1.72 | 4.47±1.28 | 0.825 | 0.62 |
| Triglycerides (mmol/L) | 1.86±0.95 | 1.77±0.86 | 1.48±0.87 | 0.318 | 0.27 |
| LDL-C (mmol/L) | 2.75±0.94 | 2.83±0.41 | 2.57±1.06 | 0.382 | 0.31 |
| HDL-C (mmol/L) | 1.16±0.34 | 1.17±0.28 | 1.18±0.37 | 0.558 | 0.48 |
| Blood glucose (mmol/L) | 5.68±1.66 | 5.32±1.75 | 5.27±2.32 | 0.667 | 0.52 |
| Glycosylated hemoglobin (%) | 5.86±0.93 | 6.19±0.86 | 5.97±0.85 | 0.582 | 0.49 |
| VOCM (ml) | 246.87±49.76 | 248.86±48.68 | 250.85±50.73 | 0.573 | 0.48 |
| LVEF (%) | 59.27±11.63 | 58.74±11.86 | 61.32±12.08 | 0.629 | 0.55 |
| Hydration volume (ml) | 845±156 | 873±136 | 857±143 | 0.595 | 0.50 |
Notes: BMI, Body Mass Index; VOCM, volume of contrast medium; LVEF, left ventricularejection fraction.